nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.12	0.197	CbGbCtD
Frovatriptan—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.113	0.185	CbGbCtD
Frovatriptan—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.113	0.185	CbGbCtD
Frovatriptan—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.102	0.167	CbGbCtD
Frovatriptan—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0857	0.14	CbGbCtD
Frovatriptan—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0775	0.127	CbGbCtD
Frovatriptan—Discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000321	0.000829	CcSEcCtD
Frovatriptan—Shock—Efavirenz—acquired immunodeficiency syndrome	0.00032	0.000827	CcSEcCtD
Frovatriptan—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00032	0.000826	CcSEcCtD
Frovatriptan—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000319	0.000825	CcSEcCtD
Frovatriptan—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000319	0.000825	CcSEcCtD
Frovatriptan—Malaise—Ritonavir—acquired immunodeficiency syndrome	0.000318	0.000822	CcSEcCtD
Frovatriptan—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000318	0.000822	CcSEcCtD
Frovatriptan—Tension—Lamivudine—acquired immunodeficiency syndrome	0.000318	0.000821	CcSEcCtD
Frovatriptan—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000318	0.000821	CcSEcCtD
Frovatriptan—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000318	0.000821	CcSEcCtD
Frovatriptan—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000317	0.00082	CcSEcCtD
Frovatriptan—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000317	0.000819	CcSEcCtD
Frovatriptan—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000317	0.000818	CcSEcCtD
Frovatriptan—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000317	0.000818	CcSEcCtD
Frovatriptan—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000317	0.000818	CcSEcCtD
Frovatriptan—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000316	0.000818	CcSEcCtD
Frovatriptan—Ill-defined disorder—Saquinavir—acquired immunodeficiency syndrome	0.000315	0.000814	CcSEcCtD
Frovatriptan—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000315	0.000814	CcSEcCtD
Frovatriptan—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000315	0.000813	CcSEcCtD
Frovatriptan—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000315	0.000813	CcSEcCtD
Frovatriptan—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000314	0.000811	CcSEcCtD
Frovatriptan—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000314	0.000811	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000314	0.000811	CcSEcCtD
Frovatriptan—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000313	0.00081	CcSEcCtD
Frovatriptan—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000312	0.000807	CcSEcCtD
Frovatriptan—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000312	0.000806	CcSEcCtD
Frovatriptan—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000312	0.000806	CcSEcCtD
Frovatriptan—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000312	0.000806	CcSEcCtD
Frovatriptan—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000311	0.000805	CcSEcCtD
Frovatriptan—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000311	0.000805	CcSEcCtD
Frovatriptan—Anorexia—Efavirenz—acquired immunodeficiency syndrome	0.00031	0.000802	CcSEcCtD
Frovatriptan—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.00031	0.000801	CcSEcCtD
Frovatriptan—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000309	0.000799	CcSEcCtD
Frovatriptan—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000309	0.000799	CcSEcCtD
Frovatriptan—Headache—Didanosine—acquired immunodeficiency syndrome	0.000307	0.000795	CcSEcCtD
Frovatriptan—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000307	0.000793	CcSEcCtD
Frovatriptan—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000307	0.000792	CcSEcCtD
Frovatriptan—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000306	0.000792	CcSEcCtD
Frovatriptan—Malaise—Saquinavir—acquired immunodeficiency syndrome	0.000306	0.000791	CcSEcCtD
Frovatriptan—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000306	0.000791	CcSEcCtD
Frovatriptan—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000306	0.00079	CcSEcCtD
Frovatriptan—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000306	0.00079	CcSEcCtD
Frovatriptan—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000305	0.000789	CcSEcCtD
Frovatriptan—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000305	0.000788	CcSEcCtD
Frovatriptan—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000304	0.000787	CcSEcCtD
Frovatriptan—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000304	0.000785	CcSEcCtD
Frovatriptan—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000303	0.000784	CcSEcCtD
Frovatriptan—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000303	0.000783	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000303	0.000783	CcSEcCtD
Frovatriptan—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000302	0.000781	CcSEcCtD
Frovatriptan—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000302	0.00078	CcSEcCtD
Frovatriptan—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000301	0.000779	CcSEcCtD
Frovatriptan—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000301	0.000778	CcSEcCtD
Frovatriptan—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000301	0.000778	CcSEcCtD
Frovatriptan—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.000301	0.000777	CcSEcCtD
Frovatriptan—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.0003	0.000776	CcSEcCtD
Frovatriptan—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.0003	0.000776	CcSEcCtD
Frovatriptan—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.0003	0.000776	CcSEcCtD
Frovatriptan—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000299	0.000774	CcSEcCtD
Frovatriptan—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000299	0.000773	CcSEcCtD
Frovatriptan—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000298	0.000771	CcSEcCtD
Frovatriptan—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000297	0.000767	CcSEcCtD
Frovatriptan—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000297	0.000767	CcSEcCtD
Frovatriptan—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000297	0.000767	CcSEcCtD
Frovatriptan—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000297	0.000767	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000296	0.000766	CcSEcCtD
Frovatriptan—Pain—Indinavir—acquired immunodeficiency syndrome	0.000295	0.000761	CcSEcCtD
Frovatriptan—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000295	0.000761	CcSEcCtD
Frovatriptan—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000294	0.000761	CcSEcCtD
Frovatriptan—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000294	0.00076	CcSEcCtD
Frovatriptan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000294	0.000759	CcSEcCtD
Frovatriptan—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000293	0.000757	CcSEcCtD
Frovatriptan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000293	0.000757	CcSEcCtD
Frovatriptan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000292	0.000756	CcSEcCtD
Frovatriptan—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000292	0.000755	CcSEcCtD
Frovatriptan—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000292	0.000755	CcSEcCtD
Frovatriptan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000292	0.000753	CcSEcCtD
Frovatriptan—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000292	0.000753	CcSEcCtD
Frovatriptan—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000291	0.000752	CcSEcCtD
Frovatriptan—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.00029	0.000751	CcSEcCtD
Frovatriptan—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00029	0.00075	CcSEcCtD
Frovatriptan—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00029	0.00075	CcSEcCtD
Frovatriptan—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000289	0.000748	CcSEcCtD
Frovatriptan—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000289	0.000747	CcSEcCtD
Frovatriptan—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000289	0.000747	CcSEcCtD
Frovatriptan—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000289	0.000747	CcSEcCtD
Frovatriptan—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000288	0.000744	CcSEcCtD
Frovatriptan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000287	0.000742	CcSEcCtD
Frovatriptan—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000286	0.00074	CcSEcCtD
Frovatriptan—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000286	0.000738	CcSEcCtD
Frovatriptan—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000285	0.000736	CcSEcCtD
Frovatriptan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000284	0.000733	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000284	0.000733	CcSEcCtD
Frovatriptan—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000283	0.000732	CcSEcCtD
Frovatriptan—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000283	0.000731	CcSEcCtD
Frovatriptan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000283	0.000731	CcSEcCtD
Frovatriptan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000283	0.00073	CcSEcCtD
Frovatriptan—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000282	0.000728	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000282	0.000728	CcSEcCtD
Frovatriptan—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000282	0.000728	CcSEcCtD
Frovatriptan—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000281	0.000726	CcSEcCtD
Frovatriptan—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000281	0.000725	CcSEcCtD
Frovatriptan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000281	0.000725	CcSEcCtD
Frovatriptan—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000281	0.000725	CcSEcCtD
Frovatriptan—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00028	0.000722	CcSEcCtD
Frovatriptan—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000279	0.000722	CcSEcCtD
Frovatriptan—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000278	0.000719	CcSEcCtD
Frovatriptan—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000278	0.000719	CcSEcCtD
Frovatriptan—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000278	0.000719	CcSEcCtD
Frovatriptan—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000278	0.000717	CcSEcCtD
Frovatriptan—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000278	0.000717	CcSEcCtD
Frovatriptan—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000277	0.000715	CcSEcCtD
Frovatriptan—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000276	0.000714	CcSEcCtD
Frovatriptan—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.000713	CcSEcCtD
Frovatriptan—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.000713	CcSEcCtD
Frovatriptan—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000276	0.000713	CcSEcCtD
Frovatriptan—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000275	0.00071	CcSEcCtD
Frovatriptan—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000274	0.000709	CcSEcCtD
Frovatriptan—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000274	0.000708	CcSEcCtD
Frovatriptan—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000273	0.000705	CcSEcCtD
Frovatriptan—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000272	0.000704	CcSEcCtD
Frovatriptan—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000272	0.000704	CcSEcCtD
Frovatriptan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000272	0.000704	CcSEcCtD
Frovatriptan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000272	0.000702	CcSEcCtD
Frovatriptan—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000271	0.0007	CcSEcCtD
Frovatriptan—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000271	0.000699	CcSEcCtD
Frovatriptan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00027	0.000697	CcSEcCtD
Frovatriptan—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000268	0.000694	CcSEcCtD
Frovatriptan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000268	0.000693	CcSEcCtD
Frovatriptan—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.000692	CcSEcCtD
Frovatriptan—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000268	0.000692	CcSEcCtD
Frovatriptan—Headache—Stavudine—acquired immunodeficiency syndrome	0.000267	0.00069	CcSEcCtD
Frovatriptan—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000267	0.00069	CcSEcCtD
Frovatriptan—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000267	0.000689	CcSEcCtD
Frovatriptan—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000266	0.000688	CcSEcCtD
Frovatriptan—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000266	0.000688	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000266	0.000688	CcSEcCtD
Frovatriptan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000266	0.000687	CcSEcCtD
Frovatriptan—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000264	0.000683	CcSEcCtD
Frovatriptan—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000264	0.000683	CcSEcCtD
Frovatriptan—Headache—Abacavir—acquired immunodeficiency syndrome	0.000263	0.00068	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000262	0.000678	CcSEcCtD
Frovatriptan—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000262	0.000677	CcSEcCtD
Frovatriptan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000262	0.000677	CcSEcCtD
Frovatriptan—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00026	0.000673	CcSEcCtD
Frovatriptan—Shock—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.000672	CcSEcCtD
Frovatriptan—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000259	0.000668	CcSEcCtD
Frovatriptan—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000257	0.000665	CcSEcCtD
Frovatriptan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000257	0.000665	CcSEcCtD
Frovatriptan—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000257	0.000663	CcSEcCtD
Frovatriptan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000257	0.000663	CcSEcCtD
Frovatriptan—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000256	0.000661	CcSEcCtD
Frovatriptan—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.00066	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000255	0.000658	CcSEcCtD
Frovatriptan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000254	0.000656	CcSEcCtD
Frovatriptan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000254	0.000656	CcSEcCtD
Frovatriptan—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000253	0.000655	CcSEcCtD
Frovatriptan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000253	0.000655	CcSEcCtD
Frovatriptan—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000253	0.000654	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000252	0.000652	CcSEcCtD
Frovatriptan—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000252	0.000651	CcSEcCtD
Frovatriptan—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000251	0.000648	CcSEcCtD
Frovatriptan—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.00025	0.000647	CcSEcCtD
Frovatriptan—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000249	0.000644	CcSEcCtD
Frovatriptan—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000249	0.000643	CcSEcCtD
Frovatriptan—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000248	0.000641	CcSEcCtD
Frovatriptan—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000247	0.000639	CcSEcCtD
Frovatriptan—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000247	0.000638	CcSEcCtD
Frovatriptan—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000246	0.000637	CcSEcCtD
Frovatriptan—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000246	0.000636	CcSEcCtD
Frovatriptan—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000246	0.000636	CcSEcCtD
Frovatriptan—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000246	0.000636	CcSEcCtD
Frovatriptan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000246	0.000636	CcSEcCtD
Frovatriptan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000245	0.000633	CcSEcCtD
Frovatriptan—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000244	0.00063	CcSEcCtD
Frovatriptan—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000244	0.00063	CcSEcCtD
Frovatriptan—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000241	0.000623	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000241	0.000622	CcSEcCtD
Frovatriptan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.00024	0.00062	CcSEcCtD
Frovatriptan—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000239	0.000618	CcSEcCtD
Frovatriptan—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000239	0.000617	CcSEcCtD
Frovatriptan—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000237	0.000613	CcSEcCtD
Frovatriptan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000237	0.000613	CcSEcCtD
Frovatriptan—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000237	0.000612	CcSEcCtD
Frovatriptan—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000237	0.000612	CcSEcCtD
Frovatriptan—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000236	0.000609	CcSEcCtD
Frovatriptan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000236	0.000609	CcSEcCtD
Frovatriptan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000235	0.000608	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000235	0.000608	CcSEcCtD
Frovatriptan—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000235	0.000607	CcSEcCtD
Frovatriptan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000233	0.000603	CcSEcCtD
Frovatriptan—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000601	CcSEcCtD
Frovatriptan—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000232	0.0006	CcSEcCtD
Frovatriptan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00023	0.000595	CcSEcCtD
Frovatriptan—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.00023	0.000594	CcSEcCtD
Frovatriptan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000229	0.000593	CcSEcCtD
Frovatriptan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000228	0.00059	CcSEcCtD
Frovatriptan—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000228	0.000589	CcSEcCtD
Frovatriptan—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000228	0.000589	CcSEcCtD
Frovatriptan—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000228	0.000588	CcSEcCtD
Frovatriptan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000228	0.000588	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.000586	CcSEcCtD
Frovatriptan—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000226	0.000584	CcSEcCtD
Frovatriptan—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000226	0.000584	CcSEcCtD
Frovatriptan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000223	0.000577	CcSEcCtD
Frovatriptan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000223	0.000575	CcSEcCtD
Frovatriptan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00022	0.000569	CcSEcCtD
Frovatriptan—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00022	0.000568	CcSEcCtD
Frovatriptan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.000566	CcSEcCtD
Frovatriptan—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.000566	CcSEcCtD
Frovatriptan—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000219	0.000566	CcSEcCtD
Frovatriptan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000218	0.000563	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000216	0.000559	CcSEcCtD
Frovatriptan—Headache—Indinavir—acquired immunodeficiency syndrome	0.000216	0.000558	CcSEcCtD
Frovatriptan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000215	0.000556	CcSEcCtD
Frovatriptan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000213	0.00055	CcSEcCtD
Frovatriptan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000212	0.000548	CcSEcCtD
Frovatriptan—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000209	0.00054	CcSEcCtD
Frovatriptan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000209	0.00054	CcSEcCtD
Frovatriptan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.000535	CcSEcCtD
Frovatriptan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.000534	CcSEcCtD
Frovatriptan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000206	0.000532	CcSEcCtD
Frovatriptan—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000205	0.000529	CcSEcCtD
Frovatriptan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000204	0.000528	CcSEcCtD
Frovatriptan—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000204	0.000527	CcSEcCtD
Frovatriptan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000204	0.000526	CcSEcCtD
Frovatriptan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000199	0.000514	CcSEcCtD
Frovatriptan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.000512	CcSEcCtD
Frovatriptan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000197	0.000509	CcSEcCtD
Frovatriptan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000196	0.000507	CcSEcCtD
Frovatriptan—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000195	0.000504	CcSEcCtD
Frovatriptan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000195	0.000503	CcSEcCtD
Frovatriptan—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000193	0.000499	CcSEcCtD
Frovatriptan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00019	0.000492	CcSEcCtD
Frovatriptan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.00049	CcSEcCtD
Frovatriptan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00019	0.00049	CcSEcCtD
Frovatriptan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000187	0.000483	CcSEcCtD
Frovatriptan—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000185	0.000478	CcSEcCtD
Frovatriptan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000183	0.000474	CcSEcCtD
Frovatriptan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.000473	CcSEcCtD
Frovatriptan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000181	0.000467	CcSEcCtD
Frovatriptan—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00018	0.000466	CcSEcCtD
Frovatriptan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.000455	CcSEcCtD
Frovatriptan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000175	0.000452	CcSEcCtD
Frovatriptan—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000174	0.000449	CcSEcCtD
Frovatriptan—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000171	0.000442	CcSEcCtD
Frovatriptan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000434	CcSEcCtD
Frovatriptan—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000166	0.000428	CcSEcCtD
Frovatriptan—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000165	0.000425	CcSEcCtD
Frovatriptan—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000157	0.000406	CcSEcCtD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	2.31e-05	0.0262	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	2.26e-05	0.0256	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	1.76e-05	0.0199	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	1.73e-05	0.0195	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	1.72e-05	0.0195	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	1.4e-05	0.0159	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	1.37e-05	0.0155	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	1.31e-05	0.0149	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	1.27e-05	0.0143	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	1.24e-05	0.014	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	1.07e-05	0.0121	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	1.05e-05	0.0118	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	1.04e-05	0.0118	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	9.85e-06	0.0111	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	9.65e-06	0.0109	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	9.64e-06	0.0109	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	9.45e-06	0.0107	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	9.45e-06	0.0107	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	9.26e-06	0.0105	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	9.26e-06	0.0105	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	9.14e-06	0.0103	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	9.06e-06	0.0103	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	9.06e-06	0.0103	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	9.04e-06	0.0102	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	8.95e-06	0.0101	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	8.85e-06	0.01	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	8.66e-06	0.00979	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	8.59e-06	0.00972	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	8.48e-06	0.00959	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	8.41e-06	0.00952	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	7.96e-06	0.009	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	7.83e-06	0.00886	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	7.67e-06	0.00867	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.36e-06	0.00833	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.36e-06	0.00833	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	7.34e-06	0.00831	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	7.26e-06	0.00822	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	7.21e-06	0.00815	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	7.21e-06	0.00815	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	7.2e-06	0.00814	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	7.04e-06	0.00797	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	6.9e-06	0.00781	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	6.9e-06	0.00781	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	6.9e-06	0.0078	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	6.82e-06	0.00771	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	6.74e-06	0.00763	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.59e-06	0.00746	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	6.46e-06	0.0073	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	6.45e-06	0.0073	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	6.41e-06	0.00725	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.34e-06	0.00718	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	6.21e-06	0.00703	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.96e-06	0.00674	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.89e-06	0.00666	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	5.84e-06	0.00661	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.84e-06	0.0066	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.77e-06	0.00652	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.6e-06	0.00634	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.6e-06	0.00634	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.6e-06	0.00633	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	5.49e-06	0.00621	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	5.49e-06	0.00621	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	5.49e-06	0.00621	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	5.49e-06	0.00621	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	5.48e-06	0.0062	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.48e-06	0.00619	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	5.36e-06	0.00607	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.34e-06	0.00604	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	5.25e-06	0.00594	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.23e-06	0.00591	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.04e-06	0.00571	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.95e-06	0.0056	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.94e-06	0.00559	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	4.92e-06	0.00557	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	4.92e-06	0.00556	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.85e-06	0.00549	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	4.73e-06	0.00535	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	4.45e-06	0.00503	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	4.39e-06	0.00497	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	4.37e-06	0.00495	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.26e-06	0.00482	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.18e-06	0.00473	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.18e-06	0.00473	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.18e-06	0.00473	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.18e-06	0.00472	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.08e-06	0.00462	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.98e-06	0.00451	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.84e-06	0.00435	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.76e-06	0.00426	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.76e-06	0.00426	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	3.69e-06	0.00418	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.52e-06	0.00398	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.38e-06	0.00383	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.37e-06	0.00381	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.31e-06	0.00375	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.3e-06	0.00373	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.23e-06	0.00366	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.23e-06	0.00366	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	3.19e-06	0.0036	CbGpPWpGaD
Frovatriptan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.19e-06	0.0036	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.18e-06	0.0036	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.17e-06	0.00358	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.17e-06	0.00358	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.17e-06	0.00358	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.17e-06	0.00358	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.1e-06	0.00351	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.1e-06	0.00351	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.06e-06	0.00346	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3e-06	0.00339	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.93e-06	0.00331	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.88e-06	0.00325	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.88e-06	0.00325	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.87e-06	0.00324	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.86e-06	0.00324	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.82e-06	0.00319	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.82e-06	0.00319	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.76e-06	0.00313	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.52e-06	0.00285	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.51e-06	0.00284	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.41e-06	0.00273	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.41e-06	0.00273	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.41e-06	0.00273	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.37e-06	0.00269	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.36e-06	0.00267	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.36e-06	0.00267	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.36e-06	0.00267	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.32e-06	0.00263	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.28e-06	0.00258	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.23e-06	0.00252	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.19e-06	0.00248	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.18e-06	0.00247	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.17e-06	0.00246	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.16e-06	0.00244	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.15e-06	0.00243	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.15e-06	0.00243	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.14e-06	0.00242	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.13e-06	0.0024	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.11e-06	0.00239	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2e-06	0.00226	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.97e-06	0.00223	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.96e-06	0.00221	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.93e-06	0.00218	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.84e-06	0.00208	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.81e-06	0.00204	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.8e-06	0.00203	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.77e-06	0.002	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.77e-06	0.002	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.7e-06	0.00192	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.7e-06	0.00192	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.66e-06	0.00188	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.66e-06	0.00188	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.63e-06	0.00185	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.62e-06	0.00183	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.61e-06	0.00182	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.57e-06	0.00177	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.49e-06	0.00169	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.47e-06	0.00166	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.35e-06	0.00153	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.29e-06	0.00146	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.27e-06	0.00144	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.27e-06	0.00143	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.27e-06	0.00143	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.27e-06	0.00143	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.25e-06	0.00142	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.25e-06	0.00141	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.23e-06	0.00139	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.16e-06	0.00132	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.14e-06	0.00129	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.14e-06	0.00129	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.12e-06	0.00126	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	9.64e-07	0.00109	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	9.5e-07	0.00107	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	9.36e-07	0.00106	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	8.69e-07	0.000983	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	8.5e-07	0.000961	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.21e-07	0.000816	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.73e-07	0.000761	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.7e-07	0.000757	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.59e-07	0.000745	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	6.56e-07	0.000742	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.02e-07	0.000568	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.99e-07	0.000565	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.96e-07	0.000447	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.87e-07	0.000438	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	3.21e-07	0.000363	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.95e-07	0.000334	CbGpPWpGaD
